DiaMedica Therapeutics

DiaMedica Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to improving the lives of people suffering from serious diseases. DiaMedica's lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic approach for treating acute ischemic stroke and chronic kidney disease.